Abstract: Oncolytic virus therapy has recently been recognized as a promising new option for cancer treatment. Oncolytic viruses replicate selectively in cancer cells,
Introduction
Oncolytic virus therapy has recently been recognized as a promising new option for the treatment of cancer. 1, 2 Its fundamental concept is simple, and relies on the fact that oncolytic viruses replicate in cancer cells and kill them by direct cytocidal effects (Fig. 1) . 1, 2 Much evidence regarding the efficacy and safety of oncolytic virus therapy has recently been acquired from both preclinical and clinical studies. [2] [3] [4] A wide variety of parental viruses has been used for these strategies, including adenoviruses, HSV-1, reoviruses, vaccinia virus, Sendai virus, NDV, measles virus and vesicular stomatitis virus. 1 The first oncolytic virus to begin clinical trials was the engineered adenovirus, ONYX-015, which contains a deletion of the E1B-55 kDa gene and can thus theoretically only replicate in cells with a p53 mutation. 5 ONYX-015 has been tested in 18 phase I and/or II trials since 1996, and has shown oncolytic activity in cancer cells with mutant p53, but only limited cytotoxicity in normal human cells with wild-type p53 function. 1, 5 The first oncolytic virus launched for clinical use was another E1B gene-deleted adenovirus termed H101 (Oncorine). 6, 7 Based on the results of a phase III clinical trial in patients with squamous cell cancers of the head and neck or esophagus, H101 was approved by the Chinese FDA in 2006, but was not approved in Western countries. 6, 7 The oncolytic HSV-1, T-VEC (talimogene laherparepvec; formerly called OncoVEX GM-CSF ), was approved for the treatment of inoperable melanoma by the US FDA in October 2015, 8 based on the promising results of a phase III clinical trial. 9 This virus, given the brand name Imlygic, was subsequently approved in Europe and Australia in 2016.
Many types of oncolytic viruses have undergone preclinical studies for the treatment of urological cancers, as well as other malignancies, and some have already been tested in clinical trials.
1,10-12 For example, a phase I trial of the third-generation oncolytic HSV-1, G47D, in patients with prostate cancer was started in 2013 and completed in 2016. In this context, we summarize the current status of clinical trials assessing oncolytic virus therapy for the three major urological cancers: prostate, bladder and renal cell cancers.
Clinical trials of oncolytic virus therapy for prostate cancer
The present review updates the information provided in a previous review of oncolytic virus therapy for prostate cancer published in 2010.
1 Approximately 1.1 million men worldwide were diagnosed with prostate cancer in 2012, resulting in more than 307 000 deaths. 13 Prostate cancer has become the most commonly diagnosed cancer in men in Japan, with a predicted annual incidence of 98 400 cases, and 12 200 deaths in 2015.
14 Although 70-80% of patients with advanced prostate cancer who receive androgen deprivation therapy show an initial response, most eventually experience disease progression. 15 Docetaxel has become an established second-line treatment for such castration-resistant prostate cancer during the past decade, and newer agents, including enzalutamide, abiraterone acetate, sipuleucel-T, cabazitaxel and radium-223, have also recently been successively launched. However, despite their survival benefits, these therapies only extended the median survival by 3-5 months, and substantial cross-resistance among them has also been reported. 16 The development of therapies with non-conventional approaches is thus still required.
Prostate cancer is a suitable target disease for oncolytic virus therapy, 1 because the prostate gland is a non-essential organ and its complete removal or ablation is therefore not life threatening, 17 and because it is easily accessible for inoculating viruses or obtaining tissue samples through a perineal or transrectal route. Additionally, serum PSA levels can be used to monitor responses to therapy. 1 To the best of our knowledge, 11 clinical trials of oncolytic virus therapy for prostate cancer have been carried out, involving the use of adenoviruses, HSV-1, reoviruses, vaccinia virus and Sendai virus as parental viruses (Table 1) .
Adenoviruses
Adenoviruses are non-enveloped, double-stranded DNA viruses, and one of the most commonly used vectors for gene therapy, including oncolytic virus therapy, 18 as represented by ONYX-015 and H101. [5] [6] [7] Several clinical trials of oncolytic adenoviruses have been carried out in patients with prostate cancer, using two general strategies: tissue/tumor-specific promoters and suicide gene therapy.
CG7060 and CG7870
ONYX-015 achieves "conditional replication" by inactivating viral genes, the functions of which could be compensated for in cancer cells, 1, 5 whereas another strategy involves placing an essential viral gene under the control of a tissue/tumorspecific promoter. 1, 19 CG7060 (also called CV706 and CN706) is a PSA-selective oncolytic adenovirus created by inserting a minimal PSA promoter into the Ad5 genome, to drive the E1A gene.
20 CG7870 (also called CV787) is another PSA-selective oncolytic adenovirus, which was designed to place both the E1A and E1B genes under the transcriptional control of prostate-specific (rat probasin and PSA, respectively) promoters, with a wild-type E3 region that suppresses the host immune system. 21 In phase I trials, CG7060 was administered intraprostatically to 20 patients with locally recurrent prostate cancer after primary radiotherapy, 22 whereas CG7870 was given intravenously to 23 patients with hormone-refractory metastatic prostate cancer. 23 Both viruses were generally well-tolerated, except for two patients in the latter trial who experienced a constellation of adverse events including thrombocytopenia, and elevated D-dimer, interleukin-6 and transaminase levels. 22, 23 PSA decreases were observed in more than 20% of patients in both trials. 22, 23 Ad5-CD/TKrep and Ad5-yCD/mutTK SR39 rep-ADP Suicide gene therapy, first reported by Moolten, 24 is based on the introduction into tumor cells of a viral or bacterial gene, which allows the conversion of a non-toxic compound (prodrug) into a lethal drug. 25 The most widely used suicide gene systems for prostate cancer are HSV-tk plus GCV or its analog acyclovir, and CD plus 5-FC. 26 By combining the concepts of suicide gene therapy and replication-competent viruses, Freytag et al. developed an oncolytic adenovirus termed Ad5-CD/TKrep containing the CD/HSV-tk fusion gene, which thus utilizes both the HSV-tk/GCV and CD/5-FC suicide gene systems. 27 Intraprostatic injection of Ad5-CD/ TKrep was tested in two clinical trials in patients with prostate cancer, including one trial of 16 patients with local recurrence after radiotherapy 28, 29 and another of 15 patients with newly diagnosed disease, in combination with 3-D conformal radiotherapy. 30 After these, Freytag et al. developed the second-generation adenovirus, Ad5-yCD/mutTK SR39 rep-ADP, based on Ad5-CD/TKrep, and tested it in another phase I trial in nine patients with newly diagnosed prostate cancer, who received it as an intraprostatic injection in combination with intensity-modulated radiotherapy. 31 More than 90% of the adverse events in all three of these trials were mild or moderate in nature. [28] [29] [30] [31] The first trial for locally recurrent prostate cancer after radiotherapy showed a decrease in serum PSA of at least 25% in more than 60% of patients. 28, 29 The combined results of the latter two trials in patients with newly diagnosed disease (n = 24) showed that just 22% of evaluable patients were positive for adenocarcinoma at their latest biopsies, which was significantly better than expected (≥40%) for this cohort of patients.
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HSV-1
HSV-1 is an enveloped double-stranded DNA virus that possesses several advantages for use as an oncolytic virus. 33, 34 HSV-1-based oncolytic virus therapy has therefore been relatively widely studied, and together with adenoviruses, HSV-1 is now a mainstay of this treatment category.
1,2 The advantages of HSV-1 for oncolytic virus therapy include the fact that its complete genome sequence was determined in 1988, 35, 36 and its gene functions in terms of pathogenicity and replication capacity have also been well studied. 37 Additionally, HSV-1 has a large genome (~152 kb), making it suitable for the insertion of foreign genes (40-50 kb), 38 whereas the high stability of its genome means that it does not integrate into the host genome and is thus unlikely to be oncogenic. 39 HSV-1 shows tropism for neural cells, but can also infect various types of cells, and its high proliferative ability allows high titers to be generated. 33 Furthermore, its sensitivity to several agents, such as acyclovir and GCV, provides a safety mechanism. 33 The first oncolytic HSV-1 was developed by Martuza et al. in 1991, using a tk-negative mutant of HSV-1 (dlsptk). 40 Viral tk is required for nucleotide metabolism, which is essential for DNA replication in non-dividing cells, and upregulation of mammalian tk compensates for this defect in cancer cells, making it possible for dlsptk to achieve "conditional replication". 41 Although dlsptk has been shown to kill glioma cells in vitro and in glioma models in vivo, 33, 40, 42 it poses a safety concern in human patients, because deletion of (21) SC (vaccinia) + IT (fowlpox) [75] Sendai virus particle (HVJ-E; GEN0101; TSD-0014)
Sendai virus (HVJ) I/II Castration resistant prostate cancer (9) IT + SC Underway the viral tk gene renders the virus insensitive to most commonly used antiherpetic drugs, such as acyclovir and GCV. 43 The developed HSV-1 are classified as first, second or third generation, according to the number of gene modifications; dlsptk with a mutation in one gene is categorized as a firstgeneration oncolytic HSV-1. For reference, T-VEC, which was approved for the treatment of inoperable melanoma by the US FDA in October 2015, is classified as a second-generation HSV-1. 8 This double-mutant HSV-1 has c34.5 and a47 deletions, and expresses human GM-CSF. 44 
G47D
G207 is one of the first oncolytic HSV-1 to have been used in clinical trials in the USA. [45] [46] [47] It was derived from HSV-1 strain F, and has deletions in both copies of the c34.5 gene, as well as a LacZ insertion inactivating the ICP6 gene (i.e. a second-generation oncolytic HSV-1). 1, 45 The c34.5 gene allows normal HSV-1 to block the anti-infective host cellinduced shut-off of protein synthesis, 33, 34, 42 whereas ICP6 encodes the large subunit of ribonucleotide reductase, which is essential for viral DNA synthesis and replication. 41, 43 Each deletion of these genes can result in conditional replication of engineered viruses, similar to the situation described for dlsptk. 33, 34 G47D is a third-generation oncolytic HSV-1 that Todo et al. developed in 2001 by adding another engineered mutation, namely the deletion of the a47 gene, to the genome of G207. 48 The structure of G47D is shown in Figure 2 . The a47 gene product, ICP47, functions to antagonize the host cell's transporter associated with antigen presentation, such that nascent multihistocompatibility complex class I molecules fail to acquire antigenic peptides, thus enabling HSV-1 to escape host immune surveillance. 49, 50 Deletion of the a47 gene therefore prevents the downregulation of multihistocompatibility complex class I expression, which could enhance the antitumor immune response. 33, 49 Furthermore, the additional deletion in G47D places the late U S 11 gene under the control of the immediate-early a47 promoter. This enhances the growth of G47D relative to G207 in cancer cells, because earlier expression of U S 11 prevents the premature termination of protein synthesis that slows the growth of c34.5-mutated HSV-1 like G207. 33, 48 G47D showed significantly higher replication capacity, increased antitumor efficacy, and preserved safety compared with G207 in a variety of tumor models, including prostate cancer. 48, [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] Based on its high antitumor efficacy and safety, a phase I-IIa clinical trial of G47Δ in patients with glioblastoma started in Japan in 2009, followed by a phase II study that started in May 2015. In addition to these trials, a phase I study of G47Δ in patients with olfactory neuroblastoma has been ongoing since September 2013.
A phase I study of G47Δ in patients with castration-resistant prostate cancer started in May 2013 and was completed in 2016 (www.umin.ac.jp, UMIN000010463). This represented the first clinical trial in the world that used oncolytic HSV-1 for treating prostate cancer. In this single-arm study, we injected G47Δ (3 9 10 8 pfu) into the prostate using a transrectal, ultrasound-guided, transperineal technique. Dose escalation was planned in three cohorts by increasing the number of dosing: patients received two doses of G47Δ in the first cohort, three times in the second and four times in the third. The treatment has been well-tolerated by patients, and no severe adverse events attributable to G47Δ have been observed so far.
Reovirus
Reoviridae is a family of viruses that can infect the gastrointestinal tract and respiratory system. Human reoviruses contain 10 segments of double-stranded RNA, and a double shell of proteins comprising the inner capsid or core and the outer capsid. Cells with an activated Ras signaling pathway support HSV-1 genome:
Genes: the replication of reoviruses, 62 whereas normal untransformed cells were shown not to be infected by reoviruses. 63 Approximately 30% of all human cancers include a mutation in the Ras protein. 63 Coffey et al. reported that a single intratumoral injection of a reovirus resulted in tumor regression in 65-80% of mice. 64 In this context, a wild-type (not engineered) reovirus has been used for oncolytic virus therapy.
Pelareorep
The oncolytic wild-type reovirus, pelareorep (REOLYSIN; Oncolytics Biotech Inc., Calgary, Alberta, Canada), was evaluated in a phase I trial in patients with advanced solid tumors, including prostate cancer. 65 Escalating intravenous doses of pelareorep up to 3 9 10 10 50% tissue culture infective doses were found to be safe, with minimal toxicity. Evidence of viral replication was found in biopsy samples, but neutralizing antibodies were also produced. A reduction in PSA level (from 100 to 50 ng/mL) in one patient with prostate cancer suggested potential efficacy. 65 A phase II trial of pelareorep was carried out in patients with stage T2 (organconfined) prostate cancer who received a single intraprostatic injection of pelareorep 3 weeks before prostatectomy. Evidence of tumor cell apoptosis was seen in four of six tumors, and the PSA level fell in one patient. No toxicity was observed, and immune cell infiltration was limited to the tumor. 66 Furthermore, a randomized phase II trial of pelareorep in combination with docetaxel for recurrent or metastatic castration-resistant prostate cancer is currently underway (www.clinicaltrials.gov, NCT01619813). In that study, patients are given either intravenous pelareorep plus docetaxel or docetaxel alone. Patient enrollment has recently been completed, and approximately 40 response-evaluable patients are enrolled in each arm.
Vaccinia virus
Vaccinia virus belongs to the poxvirus family, and has a large (~200 kb), linear double-stranded DNA genome. Poxviruses are unique in that their entire life cycle occurs in the cytoplasm, including transcription and DNA replication, thus avoiding the potentially inefficient process of nuclear translocation. 67, 68 There have been several clinical trials of vaccine therapy using poxviruses for prostate cancer, [69] [70] [71] [72] [73] [74] [75] though most of these have involved intradermal or subcutaneous administration of viral vaccines, according to the typical concept of vaccination. [69] [70] [71] [72] [73] [74] However, one of these trials utilized an intraprostatic booster vaccination in addition to the conventional subcutaneous one, with the aim of enhancing the efficacy through both direct tumor killing by the virus and indirect tumor killing through an immune-mediated response. 75 This phase I trial, which assessed the safety and feasibility of intraprostatic administration of the PSA-targeted vaccinia virus, PSA-TRICOM (PROSTVAC â ; Bavarian Nordic, Kvistgaard, Denmark), is included in Table 1 .
Sendai virus
Sendai virus, or hemagglutinating virus of Japan, is a member of the Paramyxoviridae family, and consists of a non-segmented, linear, negative-stranded RNA genome encapsulated by a nucleoprotein. 76 Kawaguchi et al. examined the direct tumor-killing activity of inactivated Sendai virus particles (also known as hemagglutinating virus of Japan envelope [HVJ-E], GEN0101 and TSD-0014) in PC-3 and DU145 hormone-resistant human prostate cancer cell lines. Infection of cells with HVJ-E produced IFN-a and IFN-b, and induced apoptosis in cancer cells. Direct injection of HVJ-E into PC-3 tumor cells in the severe combined immunodeficiency mice led to a reduction in tumor volume, and 85% of mice became tumor-free. 77 Based on these preclinical results, a phase I/II trial assessing the safety and efficacy of continuous, intratumoral and subcutaneous administration of HVJ-E in patients with castration-resistant prostate cancer is currently underway (www.umin.ac.jp, UMIN000010840). In this single-arm study, HVJ-E will be administered four times per 2 weeks and then washed out for 2 weeks, and this cycle will be repeated twice. HVJ-E will be given at a dose of 30 000 mNAU (neuraminidase assay unit) per injection, and if dose escalation is permitted by an independent data monitoring committee, another cohort will be given 60 000 mNAU of HVJ-E per injection. As of now, there have been only two clinical trials assessing oncolytic virus therapy for urological cancers in Japan: this HVJ-E trial and the said G47D trial (www.umin. ac.jp, UMIN000010463), both indicated for castration-resistant prostate cancer. Further trials of oncolytic virus therapy for urological cancers, including bladder and renal cell cancers, are expected to get underway in Japan in the near future.
Clinical trials of oncolytic virus therapy for bladder cancer
Approximately 430 000 patients worldwide were diagnosed with bladder cancer in 2012, resulting in more than 160 000 deaths, 13 whereas approximately 21 300 patients in Japan were diagnosed with bladder cancer in 2015, resulting in approximately 8100 deaths.
14 Bladder cancer is recognized as an intractable disease; most early superficial (non-muscleinvasive) bladder cancers recur after initial therapy (transurethral resection AE intravesical instillation) and require additional therapy, including cystectomy. 10 Once it has progressed to advanced disease, the median survival time is only approximately 14 months, despite current cisplatinbased chemotherapeutic regimens. 78, 79 The development of oncolytic virus therapy is thus urgently required both as an additional bladder-sparing treatment option for early superficial disease, and a novel salvage therapy for advanced disease.
The urinary bladder is a suitable target organ for oncolytic virus therapy for several reasons. The delivery of agents into the bladder through the urethra (intravesical instillation) is already established, allowing for direct virus delivery and exposure of the tumor to high virus titers. 80 This ease of access to the urothelium through the urethra also allows for frequent evaluation of treatment effects and tissue sampling. 10 Additionally, the papillary configuration of superficial bladder cancer increases the surface area for topical application, 11 and the bladder is an isolated organ with an asymmetric multilayered unit membrane, which limits systemic exposure to agents, thereby providing a margin of safety. [81] [82] [83] Furthermore, the success of BCG therapy has shown the immunosensitivity of bladder cancer, suggesting the potential usefulness of other immunomodulating therapies. 10, 11 To the best of our knowledge, four clinical trials of oncolytic virus therapy have been carried out in patients with bladder cancer, using parental viruses including adenoviruses and vaccinia virus ( Table 2) .
Adenoviruses
As for prostate cancer, the use of oncolytic virus therapy using adenoviruses has been studied for the treatment of bladder cancer.
CG0070
Ramesh et al. developed the oncolytic adenovirus CG0070, in which the human E2F-1 promoter drives expression of the E1A viral gene.
84 E2F-1 is regulated by the retinoblastoma tumor suppressor protein, which is commonly mutated in many bladder cancers, 11, 85, 86 and loss of retinoblastoma protein binding to E2F-1 results in transcriptionally active E2F.
11,87 CG0070 was also armed with human GM-CSF. 84 Burke et al. carried out a phase I trial of this virus in patients with non-muscle-invasive bladder cancer who did not respond to BCG therapy. 88 Single or multiple (every 28 days 93 or weekly 96) doses up to 3 9 10 13 virus particles were administered intravesically to 35 patients in conjunction with the transduction-enhancing agent, dodecyl maltoside. The results showed an overall response rate of 48.6% (17/35), which increased to 63.6% (14/22) in the multidose cohort. No clinically significant, treatment-related serious adverse events were reported, and the most common adverse events were grade 1-2 bladder toxicities, such as dysuria, bladder pain and frequency. 88 Based on these encouraging results, a phase II/III randomized controlled trial is currently underway to compare the effect of intravesical instillation of CG0070 with mitomycin C, IFN, valrubicin or gemcitabine in patients with non-muscle-invasive bladder cancer after BCG failure (www.clinicaltrials.gov, NCT01438112). Another single-arm phase II trial is also underway in patients with non-muscleinvasive bladder cancer who previously failed BCG therapy and refused cystectomy, who are being administered intravesical CG0070 at a dose of 10 12 virus particles weekly for 6 weeks. Patients who achieve a partial or complete response at 6 months after the first intervention will be maintained on the same induction cycle every 6 months until month 18 (www.clinicaltrials.gov, NCT02365818).
Vaccinia virus
In 2001, Gomella et al. reported the results of the first clinical study of virus therapy for bladder cancer, which involved a phase I trial of a vaccine strain of replication-competent vaccinia virus, Dryvax, for muscle-invasive bladder cancer. 89 The study examined four patients who were treated with three intravesical instillations of Dryvax at maximum doses of 10 8 pfu before cystectomy. Apart from mild local toxicity, no serious treatment-related side-effects were reported, suggesting that even wild-type vaccinia virus can be administered safely into the bladder. Post-resection evaluation showed inflammatory infiltration including dendritic cell migration to the site of virus infection, as well as evidence of virus infection in both normal and tumor cells. 10, 89 Clinical trials of oncolytic virus therapy for renal cell cancer Over 330 000 patients worldwide were estimated to be diagnosed with kidney cancer in 2012, resulting in more than 140 000 deaths, 13 and approximately 28 700 patients were diagnosed with kidney cancer in Japan in 2015, resulting in approximately 9100 deaths (note that these numbers include cases of minor urological cancers).
14 Although the prognosis of localized renal cell cancer treated with surgical resection is generally favorable, a significant number of patients present with metastatic disease at the time of diagnosis (>15%) or subsequently develop metastatic recurrence after surgery. 90, 91 Owing to its radio-and chemoresistant characteristics, metastatic renal cell cancer has been an intractable and lethal disease, with a median overall survival of just 6-13 months. 90, 91 Although recent developments in moleculartargeted therapy have improved survival, the prolongation is limited (up to 10 months), and these treatments are associated with problems, including drug resistance and adverse events. 92 More recently, several clinical trials of immune checkpoint inhibitors, including ipilimumab (Yervoy; BristolMyers Squibb, New York, NY, USA; targeting CTLA-4) and nivolumab (Opdivo; Bristol-Myers Squibb and Ono Pharmaceutical Co., Ltd., Osaka, Japan; targeting PD-1), have been carried out in patients with renal cell cancer, with some promising results compared with conventional therapies. 93 However, in addition to these, the development of a non-conventional and effective treatment modality for renal cell cancer is required. The kidney is a potentially suitable target for oncolytic virus therapy because of its easy accessibility for inoculating viruses or obtaining tissue samples via the percutaneous route, under computed tomography or ultrasonography guidance. Furthermore, responses to immunotherapy (interleukin-2, IFN-a and immune checkpoint inhibitors) have shown the immunosensitivity of renal cell cancer, implying that other immunomodulating therapies might also be effective. To the best of our knowledge, there have been four clinical trials of oncolytic virus therapy in patients with renal cell cancer, utilizing vaccinia virus and NDV as parental viruses (Table 3) .
Anticancer vaccine therapy using vaccinia virus has been well-studied in renal cell cancer, as represented by the use of a MVA) to deliver a 5T4 tumor-associated antigen (MVA-5T4; TroVax; Oxford BioMedica, Oxford, UK). Four clinical trials of MVA-5T4 for renal cell cancer have already been carried out, including a total of 89 patients. 94 There is a single case report of a patient with metastatic renal cell cancer who was treated with an attenuated vaccinia virus AS strain. 95 They showed near-complete regression of pulmonary and vertebral metastases after repeated intravenous injections of this virus, with no adverse reactions, implying the potential therapeutic efficacy of oncolytic virus therapy using vaccinia virus for renal cell cancer.
12,95
Pexa-Vec
Pexa-Vec (pexastimogene devacirepvec; formerly called JX-594) is a tk gene-inactivated oncolytic vaccinia virus expressing GM-CSF and Lac-Z transgenes, designed to destroy cancer cells through replication-dependent cell lysis and stimulation of antitumoral immunity. 96, 97 Both intratumoral and intravenous administrations of Pexa-Vec have been tested in several phase I and/or II clinical trials in patients with hepatocellular carcinoma, colorectal cancer, renal cell carcinoma and melanoma. [98] [99] [100] [101] [102] [103] [104] [105] Pexa-Vec was generally well-tolerated in all these studies, and a trial evaluating its intravenous administration for the treatment of advanced solid tumors resistant to multiple other treatments established a maximum feasible intravenous dose of 3 9 10 7 pfu/kg (equivalent to a total dose of about 2 9 10 9 pfu).
100
A phase II trial recently evaluated Pexa-Vec in 17 patients with metastatic refractory renal cell carcinoma who received weekly intravenous infusions of Pexa-Vec (median infusions = 8; range 5À12). 104, 105 The treatment regimen was welltolerated, and the most common adverse events were transient influenza-like illness (n = 17; 100%), asthenia (n = 8; 47%), anemia (n = 5; 29%) and nausea (n = 5; 29%). All patients were evaluable radiographically at week 6, and the Response Evaluation Criteria in Solid Tumors response rate was 6% (1 partial response, which was classified as a complete response at week 36), and the disease-control rate was 76% at week 6.
104
NDV
NDV is a paramyxovirus that causes potentially fatal Newcastle disease in a wide variety of birds. 106, 107 Although NDV can also infect humans, it is not usually particularly virulent, and only causes mild flu-like symptoms or conjunctivitis and/or laryngitis. 106 The perception that NDV can replicate up to 10 000 times more in human cancer cells than in most normal human cells 107 has prompted interest in this virus as a potential anticancer agent.
108 NDV-based cancer vaccine therapies have mainly been evaluated in patients with locally-advanced or metastatic renal cell carcinoma, [109] [110] [111] and direct infections with lytic NDV strains (MTH-68 in a phase II trial 112 and PV701 in two phase II trials 113, 114 ) have been evaluated in patients with several cancer types, including renal cell cancer. However, NDV has not currently been approved by the US FDA 108 because of critical drawbacks in some trials, including the non-randomized assignment of patients and the inclusion of significantly more patients who had undergone conventional therapy within the 3 months before virus therapy. 112 Notably, PV701 trials carried out in the USA and Canada have raised possible concerns that repeated administration of NDV might cause the host immune system to produce virus-neutralizing antibodies. 108, 113, 114 Overall, the effectiveness of oncolytic virus therapy using NDV remains controversial and warrants further evaluation.
Conclusions
The present review summarized the current status of clinical trials assessing oncolytic virus therapy for prostate, bladder and renal cell cancers. These trials have mainly used adenoviruses, HSV-1, reoviruses, vaccinia virus, Sendai virus and NDV as parental viruses. Characteristics of these viruses are briefly summarized in Table S1 . Considering its efficacy and safety, oncolytic virus therapy might become the fourth major treatment option for urological cancers in the near future, following surgery, radiotherapy and chemotherapy. 
